Xenon Pharmaceuticals Inc... (XENE)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
40.00
-0.11 (-0.27%)
At close: Jan 28, 2025, 1:55 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
Revenue | n/a | 9.43M | 18.44M | 32.17M | 6.83M | n/a | 311.00K | 1.80M | 15.58M | 28.37M | 27.36M | 14.31M | 6.92M |
Cost of Revenue | 167.51M | 105.77M | 75.46M | 50.52M | 38.84M | 6.00M | 25.57M | 1.11M | 2.76M | 5.90M | 6.21M | 7.32M | n/a |
Gross Profit | -167.51M | -96.33M | -57.03M | -18.36M | -32.02M | -6.00M | -25.26M | 689.00K | 12.81M | 22.47M | 21.15M | 6.99M | 6.92M |
Operating Income | -214.05M | -129.14M | -78.99M | -31.30M | -42.82M | -38.02M | -32.58M | -24.82M | -9.36M | 11.11M | 9.71M | -3.15M | -12.11M |
Interest Income | 27.62M | 8.71M | 466.00K | 2.28M | 2.35M | 1.22M | 477.00K | 504.00K | 542.00K | 568.00K | 338.00K | 144.00K | 153.00K |
Pretax Income | -182.69M | -125.25M | -78.89M | -29.09M | -41.62M | -34.50M | -30.70M | -23.00M | -15.75M | 13.02M | 12.03M | -4.30M | -11.99M |
Net Income | -182.39M | -125.37M | -78.88M | -28.84M | -41.59M | -34.50M | -30.70M | -23.00M | -15.75M | 13.02M | 12.03M | -4.30M | -11.99M |
Selling & General & Admin | 46.54M | 32.81M | 21.97M | 12.94M | 10.80M | 8.38M | 7.31M | 6.79M | 9.79M | 5.50M | 5.34M | 7.01M | 6.73M |
Research & Development | 167.51M | 105.77M | 75.46M | 50.52M | 38.84M | 23.63M | 25.57M | 19.83M | 15.15M | 11.77M | 12.30M | 10.46M | 12.30M |
Other Expenses | -167.51M | 3.89M | 105.00K | 2.21M | n/a | 4.40M | n/a | n/a | -6.39M | n/a | n/a | n/a | n/a |
Operating Expenses | 46.54M | 138.58M | 97.43M | 63.47M | 49.65M | 32.02M | 32.89M | 26.62M | 24.94M | 17.26M | 17.64M | 17.46M | 19.03M |
Interest Expense | n/a | n/a | n/a | 484.00K | 1.43M | 1.39M | n/a | n/a | n/a | n/a | 64.00K | 93.00K | 91.00K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 214.05M | 138.58M | 97.43M | 63.47M | 49.65M | 38.02M | 32.89M | 26.62M | 24.94M | 17.26M | 17.64M | 17.46M | 19.03M |
Income Tax | -292.00K | 118.00K | -6.00K | -257.00K | -23.00K | 4.91M | -1.87M | -1.82M | -1.04M | n/a | 64.00K | 93.00K | 91.00K |
Shares Outstanding (Basic) | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 17.99M | 15.49M | 14.28M | 3.17M | 9.09M | 9.09M | 9.08M |
Shares Outstanding (Diluted) | 66.89M | 60.54M | 43.63M | 34.54M | 25.94M | 19.43M | 18.00M | 15.49M | 14.28M | 3.96M | 9.83M | 9.83M | 9.74M |
EPS (Basic) | -2.73 | -2.07 | -1.81 | -0.83 | -1.6 | -1.78 | -1.71 | -1.48 | -1.1 | 4.11 | 0.42 | -0.47 | -1.32 |
EPS (Diluted) | -2.73 | -2.07 | -1.81 | -0.83 | -1.6 | -1.78 | -1.71 | -1.48 | -1.1 | 3.28 | 0.39 | -0.44 | -1.23 |
EBITDA | -210.51M | -127.52M | -78.09M | -27.97M | -39.76M | -32.54M | -30.05M | -23.95M | -8.32M | 11.84M | 10.42M | -3.42M | -10.77M |
Depreciation & Amortization | 3.54M | 1.62M | 906.00K | 644.00K | 429.00K | 586.00K | 649.00K | 864.00K | 1.04M | 738.00K | 705.00K | 786.00K | 1.13M |